Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer

por Farrell, Colm, Schweizer, Charles, Wustner, Jason, Weil, Susan, Namiki, Masayuki, Nakano, Tomohisa, Nakai, Kenya, Phillips, Martin D.
Publicado 2012

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)

por Kim, Kenneth H., Jelovac, Danijela, Armstrong, Deborah K., Schwartz, Benjamin, Weil, Susan C., Schweizer, Charles, Alvarez, Ronald D.
Publicado 2015

Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging

por Hekman, Marlène C. H., Boerman, Otto C., Bos, Desirée L., Massuger, Leon F. A. G., Weil, Susan, Grasso, Luigi, Rybinski, Katherine A., Oosterwijk, Egbert, Mulders, Peter F. A., Rijpkema, Mark
Publicado 2017

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue...

por Jones, Robin L., Chawla, Sant P., Attia, Steven, Schöffski, Patrick, Gelderblom, Hans, Chmielowski, Bartosz, Le Cesne, Axel, Van Tine, Brian A., Trent, Jonathan C., Patel, Shreyaskumar, Wagner, Andrew J., Chugh, Rashmi, Heyburn, John W., Weil, Susan C., Wang, Wenquan, Viele, Kert, Maki, Robert G.
Publicado 2019